Últimas noticias sobre 2seventy bio (NASDAQ:TSVT) Bolsa

2seventy bio

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

2seventy bio Inc

ABM Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) shares are trading higher after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44271643/abm-reports-first-quarter-fiscal-2025-results" rel="noreferrer noopener">reported&nbsp;first-quarter&nbsp;FY25&nbsp;earnings.</a>
Sales grew&nbsp;2.2% year over year to&nbsp;$2.11 billion, beating the consensus of&nbsp;$2.09 billion.
Revenue growth was driven by Technical Solutions (+22% Y/Y) and Aviation (+8.2% Y/Y), with Education revenue rose 2.4% Y/Y.
Operating profit rose 4.7% Y/Y to&nbsp;$77.6 million in the quarter. Adjusted EBITDA rose to&nbsp;$120.6 million from $116.7 million a year ago quarter, with the adjusted EBITDA margin stood at&nbsp;5.9%&nbsp;(flat Y/Y).
Adjusted EPS of&nbsp;87 cents beat&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of&nbsp;78 cents</a>.
Net cash used in operating activities was&nbsp;$106.2 million, and free cash flow was negative&nbsp;$122.9 million, primarily reflecting a temporary increase in working capital due to the transition to the new ERP system.
As of January-end, ABM held cash and equivalents of&nbsp;$59.0 million.
ABM declared a cash dividend of&nbsp;$0.265 per common share, payable on May 5, 2025, to shareholders of record on April 3, 2025.
Scott Salmirs, President &amp; Chief Executive Officer, said, &#8220;We also successfully launched our cloud-based enterprise resource planning (ERP) system in the first quarter for B&amp;I and M&amp;D. While we encountered temporary delays in cash flow, we anticipate improvement next quarter and full normalization in the second half.&#8221;
&#8221;Once fully implemented, we expect this system will drive significant cost efficiencies, enhance our ability to capture synergies from M&amp;A, and provide real-time analytics and reporting to unlock commercial opportunities."
Outlook: ABM raised the lower end of its FY25 adjusted EPS outlook by $0.05, now expecting it to be $3.65<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> to $3.80 versus the consensus of $3.73</a>.
The company continues to see an adjusted EBITDA margin of 6.3%- 6.5% and anticipates interest expense of $80 million &#8211; $84 million.
Salmirs added, &#8220;We are confident that the commercial real estate markets we serve, particularly high-quality office buildings, will return to growth in 2025. This optimism is supported by a 24% sequential increase in U.S. commercial office leasing activity during the fourth quarter of the calendar year.&#8221;
&#8221;Additionally, we expect our other end markets to remain broadly healthy. Coupled with our strong sales pipeline and market-leading technology, these factors strengthen our confidence in achieving our 2025 objectives.&#8221;
Investors can gain exposure to the stock via&nbsp;VanEck Environmental Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVX#NYSE">EVX</a>).
Price Action: ABM shares are up 0.86% at $50.26 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44270724/rocket-lab-takes-a-bold-leap-75-million-offer-for-mynaric-to-boost-satellite-tech-sda-contracts" target="_blank" rel="noreferrer noopener">Rocket Lab Expands Its Space Arsenal: Eyes Laser Tech Boost With Mynaric Buyout</a></li>
</ul>

Earnings

Equities

Mid Cap

News

Guidance

Movers

Market Vectors Environmental Services Index Fund

ABM Q1 Earnings: Sales And EPS Beat, Cash Flow Challenges, Outlook Boost And More

Ocean Power Technologies, Inc. (NYSE:<a href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) ("OPT" or the "Company"), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced it received a binding letter of intent to deploy a PowerBuoy&#xAE; for an undisclosed customer to demonstrate the survivability and suitability of the system for certain multidomain defense and security applications in extreme sea conditions. This follows the signing of a teaming agreement with a major international defense contractor last year to provide its Merrows&#x2122; suite of solutions with a focus on certain geographic regions.

OPTT

Ocean Power Technologies Announces Binding LOI To Deploy AI-Capable PowerBuoy For A Undisclosed Customer To Demonstrate The Survivability And Suitability Of The System For Certain Multidomain Defense And Security Applications In Extreme Sea Conditions

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) with a Buy and maintains $15 price target.

Price Target

Reiteration

Analyst Ratings

HUMA

HC Wainwright & Co. Reiterates Buy on Humacyte, Maintains $15 Price Target

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the information technology sector.
<h3 class="wp-block-heading">Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>)</h3>
<ul>
<li>Dividend Yield: 4.10%</li>
<li>Goldman Sachs analyst Toshiya Hari maintained a Neutral rating and cut the price target from $92 to $70 on Feb. 6, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Stifel analyst Ruben Roy downgraded the stock from Buy to Hold and lowered the price target from $105 to $62 on Feb. 6, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On Feb. 5, Skyworks issued second-quarter adjusted EPS guidance below estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest SWKS <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="911" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195035/image-80.png" alt="" class="wp-image-819697" style="width:532px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195035/image-80.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195035/image-80-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195035/image-80-768x704.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>)</h3>
<ul>
<li>Dividend Yield: 4.05%</li>
<li>Loop Capital analyst Annada Baruah maintained a Hold rating and cut the price target from $35 to $30 on March 4, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Barclays analyst Tim Long maintained an Equal-Weight rating and raised the price target from $35 to $36 on Feb. 28, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On Feb. 27, HP issued second-quarter adjusted EPS guidance below estimates..</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">HPQ news</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/df77bbb1-43a4-4442-b721-878eebbeb2c1" alt="" style="width:587px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Opera Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>)</h3>
<ul>
<li>Dividend Yield: 4.58%</li>
<li>TD Cowen analyst Lance Vitanza maintained a Buy rating and raised the price target from $25 to $28 on Oct. 30, 2024. This analyst has an accuracy rate of 76%.</li>
<li>B. Riley Securities analyst Lee Krowl reiterated a Buy rating and increased the price target from $24 to $25 on Oct. 30, 2024. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On Feb. 27, Opera reported better-than-expected fourth-quarter revenue results and issued first-quarter revenue guidance above estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">OPRA news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195149/image-82.png" alt="" class="wp-image-819699" style="width:580px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195149/image-82.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195149/image-82-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195149/image-82-768x708.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44245496/top-3-health-care-stocks-that-may-keep-you-up-at-night-in-q1">Top 3 Health Care Stocks That May Keep You Up At Night In Q1</a></li>
</ul>

Dividends

Pre-Market Outlook

Markets

Trading Ideas

OPRA

SWKS

Wall Street's Most Accurate Analysts Weigh In On 3 Tech Stocks With Over 4% Dividend Yields

Morgan Stanley analyst Erik Woodring maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Overweight and lowers the price target from $275 to $252.

AAPL

Morgan Stanley Maintains Overweight on Apple, Lowers Price Target to $252

The most oversold stocks in the financial sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Payoneer Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYO#NASDAQ">PAYO</a>)</h3>
<ul>
<li>On Feb. 27, Payoneer Global reported worse-than-expected fourth-quarter EPS results. The company's stock fell around 29% over the past month and has a <a href="https://www.benzinga.com/quote/PAYO">52-week low of $4.22</a>.</li>
<li>RSI Value: 28.9</li>
<li>PAYO Price Action: Shares of Payoneer Global gained 0.3% to close at $7.06 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">PAYO news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11192933/image-77.png" alt="" class="wp-image-819686" style="width:645px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11192933/image-77.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11192933/image-77-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11192933/image-77-768x703.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">KKR &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On March 5, the company disclosed definitive agreements to sell the Japanese supermarket chain Seiyu to Trial Holdings, Inc. for 380 billion yen ($2.5 billion). The company's stock fell around 21% over the past month and <a href="https://www.benzinga.com/quote/KKR">has a 52-week low </a>of $91.92.</li>
<li>RSI Value: 27.8</li>
<li>KKR Price Action: Shares of KKR rose 3.6% to close at $112.11 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">KKR stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="922" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193020/image-78.png" alt="" class="wp-image-819687" style="width:586px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193020/image-78.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193020/image-78-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193020/image-78-768x698.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Piper Sandler Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PIPR#NYSE">PIPR</a>)</h3>
<ul>
<li>On March 11, Piper Sandler expanded its research distribution with new office opening in Zurich. The company's stock fell around 18% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/PIPR">low of $183.58.</a></li>
<li>RSI Value: 29.6</li>
<li>PIPR Price Action: Shares of Piper Sandler gained 3.1% to close at $250.49 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">PIPR shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="887" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193110/image-79.png" alt="" class="wp-image-819688" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193110/image-79.png 887w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193110/image-79-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193110/image-79-768x721.png 768w" sizes="(max-width: 887px) 100vw, 887px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44245496/top-3-health-care-stocks-that-may-keep-you-up-at-night-in-q1">Top 3 Health Care Stocks That May Keep You Up At Night In Q1</a></li>
</ul>

Long Ideas

PAYO

PIPR

Top 3 Financial Stocks That Could Blast Off This Month

<a href="https://www.bakerhughes.com/company/news/us-department-defense-grants-baker-hughes-awardable-status-development-geothermal">https://www.bakerhughes.com/company/news/us-department-defense-grants-baker-hughes-awardable-status-development-geothermal</a>
&nbsp;
<ul>
<li>Baker Hughes now eligible to develop utility-scale geothermal power plants to supply U.S. military bases</li>
<li>U.S military leveraged Tradewinds procurement process for adoption of resilient energy technologies&nbsp;</li>
</ul>
HOUSTON and LONDON – March 12, 2025 – Baker Hughes, an energy technology company, announced Wednesday that it was selected by the U.S. Air Force and the Department of Defense's Chief Digital and Artificial Intelligence Office (CDAO) to explore opportunities to tap into America's abundant geothermal energy supply to enhance the country's national security.
Having achieved "Awardable" status, Baker Hughes can now explore developing utility-scale geothermal power plants to supply U.S. military bases around the globe with reliable and cost-effective electricity, even during a grid outage. &nbsp;

"U.S. Department Of Defense Grants Baker Hughes 'Awardable' Status For Development Of Geothermal Power Solutions" - Baker Hughes

Telsey Advisory Group analyst Sarang Vora maintains Westrock Coffee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) with a Outperform and maintains $9 price target.

WEST

Telsey Advisory Group Maintains Outperform on Westrock Coffee, Maintains $9 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Buy and raises the price target from $73 to $75.

LEGN

HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $75

Telsey Advisory Group analyst Dana Telsey maintains J.Jill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) with a Market Perform and maintains $31 price target.

JILL

Telsey Advisory Group Maintains Market Perform on J.Jill, Maintains $31 Price Target

Vera Bradley Sees FY26 EPS Of ($0.15) Vs. $0.1 Est.

Stifel analyst Brian Chin maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Hold and lowers the price target from $125 to $110.

Stifel Maintains Hold on Teradyne, Lowers Price Target to $110

Stock Split

NAOV

NanoVibronix Announces 1-for-11 Reverse Stock Split, Effective Mar. 14

Clene, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-regimen, post hoc analysis of long-term survival in HEALEY ALS Platform Trial participants. The analyses further substantiate that treatment with CNM-Au8&#xAE; 30 mg delivers a significant survival benefit for people living with ALS.
New Survival Analyses The analyses compared survival in participants who received CNM-Au8 30 mg (Regimen C) to those of Regimen A in the HEALEY ALS Platform Trial. Regimen A provided a large concurrent control group vs. CNM-Au8 treatment using the same randomization criteria established within the HEALEY master protocol. Long-term survival status, determined through public records and site reporting, was evaluated over a follow-up period of up to 48 months. 78% of participants across both groups received standard ALS background therapy (riluzole, edaravone, or both) at baseline.

Biotech

General

CLNN

Clene Announced New Evidence From A Cross-Regimen, Post Hoc Analysis Of Long-Term Survival In HEALEY ALS Platform Trial Participants

Foremost Clean Energy Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/FMST#NASDAQ">FMST</a>) (CSE:<a href="https://www.benzinga.com/stock/FAT#CSE">FAT</a>) ("Foremost" or the "Company") is pleased to announce its plans for a $6.5 million exploration program in 2025 (the "Program") across its portfolio of uranium properties in the Athabasca Basin region in northern Saskatchewan. The Program includes the recently announced follow-up drill program on the Hatchet Lake Uranium Property ("Hatchet") as well as planned exploration on the Murphy Lake South, GR, Blackwing, Wolverine, and CLK properties.
&nbsp;
Following an initial evaluation of the exploration potential of the 10 properties under option from Denison Mines Corp. ("Denison")(TSX:<a class="ticker" href="https://www.benzinga.com/stock/DML#TSX">DML</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNN#NYSE">DNN</a>), Foremost identified several exploration priorities for 2025. The extensive Program will include drilling, geophysical surveys, and geochemical exploration with a focus on identifying and testing discovery-ready targets across the Athabasca Basin. Utilizing systematic and disciplined testing of discovery-ready drill targets, the program is expected to also generate additional new exploration targets on several under-explored properties.

FMST

TSX:DML

Foremost Clean Energy Announces $6.5M Uranium Exploration Program Across Athabasca Basin As Well As Planned Exploration on The Murphy Lake South, GR, Blackwing, Wolverine, And CLK Properties

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Market Perform and lowers the price target from $6 to $5.

EWCZ

Telsey Advisory Group Maintains Market Perform on European Wax Center, Lowers Price Target to $5

Vera Bradley Sees FY26 Net Revenue Of $280M Vs. $398.545M Est.

NVEE

NV5 Acquires Herman Cx, Terms not Diclosed

Emergent BioSolutions Announces Agreement For Investment Into Swiss Rockets

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4381328-1&amp;h=2654247744&amp;u=http%3A%2F%2Fwww.axcelis.com%2F&amp;a=Axcelis+Technologies">Axcelis Technologies</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced today that its Board of Directors has approved an additional $100 million in share repurchase authorization. This approval brings the current outstanding repurchase authorization to $215 million.

Buybacks

ACLS

Axcelis Announces $100M Increase To Share Repurchase Authorization; Approval Brings The Current Outstanding Repurchase Authorization To $215M

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results

2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

TSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to Shareholders

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders

Comments

2seventy bio

Noticias

Últimas noticias sobre 2seventy bio (NASDAQ:TSVT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL